Health and Healthcare

Celldex Therapeutics : CLDX

All Celldex Therapeutics Articles

48 Articles

Chris Lange | Sep 14, 2016 at 8:20 AM EDT

Key FDA Decisions and Trial Results Coming in the Next 2 Months

24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in…

Chris Lange | Sep 8, 2016 at 8:05 AM EDT

Key FDA Decisions and Trial Results Expected in October

24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in October. These…

Chris Lange | May 29, 2016 at 10:15 AM EDT

Key Movers to Look for Ahead of ASCO

The American Society of Clinical Oncology (ASCO) is gearing up for its annual meeting. At this meeting, cancer drug developers…

Chris Lange | May 19, 2016 at 10:20 AM EDT

8 Stocks on the Move After ASCO Cancer Abstracts

ASCO has just released the abstracts for its exhibitors ahead of the conference. For investors and analysts, sometimes winners or…

Chris Lange | May 12, 2016 at 7:40 AM EDT

ASCO Could Make or Break These 7 Cancer Drug Trials

The king of biotech and pharma events is about to take place. The 2016 annual meeting of the American Society…

Chris Lange | Mar 13, 2016 at 10:10 AM EDT

6 Top Companies That Destroyed Shareholders Last Week

Although stocks now are beginning to make a comeback, there are still some that are slowing this recovery and punishing…

Paul Ausick | Mar 11, 2016 at 4:04 PM EST

The 52-Week Low Club for Friday

March 11, 2016: Here are four stocks trading with heavy volume among 16 equities making new 52-week lows in Friday’s…

Paul Ausick | Mar 9, 2016 at 4:04 PM EST

The 52-Week Low Club for Wednesday

March 9, 2016: Here are four stocks trading with heavy volume among 26 equities making new 52-week lows in Wednesday’s…

Paul Ausick | Mar 8, 2016 at 4:04 PM EST

The 52-Week Low Club for Tuesday

March 8, 2016: Here are four stocks trading with heavy volume among 18 equities making new 52-week lows today. Performance…

Jon C. Ogg | Mar 8, 2016 at 8:55 AM EST

Top Analyst Upgrades and Downgrades: AutoNation, Celldex, EP Energy, Shopify, Sony, Urban Outfitters, Valeant and More

The top analyst upgrades, downgrades and initiations seen on Tuesday, March 8, include AutoNation, Celldex Therapeutics, EP Energy, Shopify, Sony,…

Paul Ausick | Mar 7, 2016 at 4:04 PM EST

The 52-Week Low Club for Monday

March 7, 2016: Here are four stocks trading with heavy volume among 12 equities making new 52-week lows today. Celldex…

Chris Lange | Mar 7, 2016 at 11:40 AM EST

Is This the Start of the Final Implosion at Celldex?

Celldex Therapeutics Inc. (NASDAQ: CLDX) got burned in Monday’s regular trading session and ultimately saw its shares fall by over…

Lee Jackson | Dec 17, 2015 at 8:20 AM EST

Top Cowen Health Care and Biotech Best Idea Stock Picks for 2016

All these Cowen picks offer compelling values for 2016, and all have backed up enough in price for investors to…

Lee Jackson | Mar 4, 2015 at 8:35 AM EST

The 5 Most Loved Biotech Stocks of Portfolio Managers

A big part of the Nasdaq is biotech, and a new report from Cowen details the stocks that big money…

Jon C. Ogg | Sep 26, 2014 at 8:40 AM EDT

Top Analyst Upgrades and Downgrades: Altria, Celldex, Linkedin, Nike, Seadrill, Verizon and More

These are the top analyst upgrades, downgrades and initiations covered by 24/7 Wall St. on Friday, September 26, 2014.

1 2 3 4

Celldex Therapeutics : CLDX

All Celldex Therapeutics Articles

Key FDA Decisions and Trial Results Coming in the Next 2 Months

Key FDA Decisions and Trial Results Expected in October

Key Movers to Look for Ahead of ASCO

8 Stocks on the Move After ASCO Cancer Abstracts

ASCO Could Make or Break These 7 Cancer Drug Trials

6 Top Companies That Destroyed Shareholders Last Week

The 52-Week Low Club for Friday

The 52-Week Low Club for Wednesday

The 52-Week Low Club for Tuesday

Top Analyst Upgrades and Downgrades: AutoNation, Celldex, EP Energy, Shopify, Sony, Urban Outfitters, Valeant and More

The 52-Week Low Club for Monday

Is This the Start of the Final Implosion at Celldex?

Top Cowen Health Care and Biotech Best Idea Stock Picks for 2016

The 5 Most Loved Biotech Stocks of Portfolio Managers

Top Analyst Upgrades and Downgrades: Altria, Celldex, Linkedin, Nike, Seadrill, Verizon and More

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

This Dividend ETF Is up 30% in 6 Months With a 3.7% Dividend Yield

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Long-Term Care Could Cost This 68-Year-Old Couple $380,000 and Their $2.1 Million Portfolio Is Not Structured for It

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Celldex Therapeutics : CLDX

All Celldex Therapeutics Articles

Key FDA Decisions and Trial Results Coming in the Next 2 Months

Key FDA Decisions and Trial Results Expected in October

Key Movers to Look for Ahead of ASCO

8 Stocks on the Move After ASCO Cancer Abstracts

ASCO Could Make or Break These 7 Cancer Drug Trials

6 Top Companies That Destroyed Shareholders Last Week

The 52-Week Low Club for Friday

The 52-Week Low Club for Wednesday

The 52-Week Low Club for Tuesday

Top Analyst Upgrades and Downgrades: AutoNation, Celldex, EP Energy, Shopify, Sony, Urban Outfitters, Valeant and More

The 52-Week Low Club for Monday

Is This the Start of the Final Implosion at Celldex?

Top Cowen Health Care and Biotech Best Idea Stock Picks for 2016

The 5 Most Loved Biotech Stocks of Portfolio Managers

Top Analyst Upgrades and Downgrades: Altria, Celldex, Linkedin, Nike, Seadrill, Verizon and More

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

This Dividend ETF Is up 30% in 6 Months With a 3.7% Dividend Yield

Featured Reads

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Long-Term Care Could Cost This 68-Year-Old Couple $380,000 and Their $2.1 Million Portfolio Is Not Structured for It